scholarly journals Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial

BMJ Open ◽  
2017 ◽  
Vol 7 (6) ◽  
pp. e014591 ◽  
Author(s):  
Fabian Proft ◽  
Burkhard Muche ◽  
Joachim Listing ◽  
Valeria Rios-Rodriguez ◽  
Joachim Sieper ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Structural Damage ◽  
Multicenter Trial ◽  
Open Label ◽  
Randomized Controlled ◽  
Effect Of Treatment ◽  
Inflammatory Drugs ◽  
Necrosis Factor

MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib

2008 ◽  
Vol 68 (9) ◽  
pp. 1466-1469 ◽  
Author(s):  
S J Jarrett ◽  
F Sivera ◽  
L S Cawkwell ◽  
H Marzo-Ortega ◽  
D McGonagle ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Symptomatic Treatment ◽  
Response Criteria ◽  
Bone Lesions ◽  
Open Label ◽  
Clinical Variables ◽  
Factor Therapy ◽  
Necrosis Factor

Objective:To describe and assess the response to short-term etoricoxib as shown by MRI and clinical variables in patients with ankylosing spondylitis (AS) selected for eligibility for anti-tumour necrosis factor therapy.Methods:In a 6-week open-label study, 22 patients with AS and eligible for biological therapy were treated with 90 mg of etoricoxib daily. Clinical and laboratory parameters were obtained and MRI of the sacroiliac joints and the lower thoracic and lumbar spine performed at baseline and at week 6. The primary end point was the proportion of patients fulfilling the SpondyloArthritis international Society (ASAS) response criteria for biological therapies (ASASBIO) while secondary end points included the change in MRI-determined bone lesions.Results:Eight of 20 completers improved enough to meet the ASASBIO response criteria and most clinical variables improved significantly. Fifteen patients had a total of 63 MRI-detectable lesions; overall, 13/60 lesions with paired scans either resolved completely or improved, while five lesions worsened or appeared during treatment.Conclusion:Etoricoxib is an effective symptomatic treatment for patients with AS; however, its effect on MRI-detected lesions is small. Further studies are needed to determine the effect of etoricoxib on MRI-determined bone oedema.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

2007 ◽  
Vol 67 (9) ◽  
pp. 1276-1281 ◽  
Author(s):  
M Rudwaleit ◽  
S Schwarzlose ◽  
E S Hilgert ◽  
J Listing ◽  
J Braun ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Clinical Response ◽  
Tumour Necrosis Factor ◽  
Tumour Necrosis ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document